According to the new market research report by IMARC Group " Infertility Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027”.

Infertility drugs are a diverse range of medications designed to assist individuals in treating infertility by stimulating or regulating ovulation, thereby enhancing the chances of natural conception. These drugs encompass a variety of options, including metformin, clomiphene citrate, gonadotrophins, letrozole, bromocriptine, and bribing. Physicians and doctors prescribe these medications following a thorough assessment that may involve ovulation testing, hysterosalpingography, and ovarian reserve testing. Recommendations for specific drugs are made after evaluating hormone levels, such as thyroid and pituitary hormones that play a crucial role in reproductive processes, as well as interpreting the results of various imaging tests like pelvic ultrasounds and Sono hysterogram.

The global infertility drugs market size reached US$ 3.8 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 5.2 Billion by 2028, exhibiting a growth rate (CAGR) of 5.24% during 2023-2028.

Market Trends -  

Currently, the market is being influenced by several factors that contribute to the increasing prevalence of infertility. Unhealthy lifestyle habits and the consumption of high-calorie diets are primary contributors to this trend. Additionally, the market growth is due to the growing awareness of infertility drugs and their beneficial aspects. The rising incidences of polycystic ovarian disease, hormonal imbalance, and obesity among women are also creating a positive market outlook. Furthermore, investments in the development of innovative drugs and advancements in the medical industry to enhance the quality of healthcare services are driving the market's expansion.

Key Market Segmentation:

The report provides detailed segmentation of the Global Infertility Drugs Market based on drug class, route of administration, distribution channel and end user.

Breakup by Drug Class:

  • Gonadotropin
  • Aromatase Inhibitors
  • Selective Estrogen Receptor Modulators (SERMs)
  • Biguanides
  • Others

Breakup by Route of Administration:

  • Oral
  • Intravenous
  • Subcutaneous
  • Intramuscular

Breakup by Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Others

Breakup by End User:

  • Male
  • Female

Breakup by Region:

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

Key Market Players:

The report provides a comprehensive analysis of the industry key players listed below:

The major players in the market are: Abbott Laboratories, Bayer AG, Ferring Pharmaceuticals, Livzon Pharmaceutical Group Inc., Mankind Pharma, Merck & Co. Inc., Merck KGaA, Novartis AG, Pfizer Inc., Sanofi S.A. and Theramex